Loading stock data…
Xeris Biopharma Holdings (XERS)
$7.74+0.05 (+0.65%)
After Hours$7.71-0.03 (-0.39%)· Last close Jun 29
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xeris Biopharma Holdings, Inc. in the Healthcare sector is trading at $7.74 with a market capitalization of $1.2B. Wall Street consensus targets $11.29 (7 analysts), implying a +45.8% move over the next 12 months. The stock is currently 23% below its 52-week high of $10.08, remaining 10.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +45.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $83.13M↓ | $85.81M↑ | $74.38M↑ | $71.54M↑ | $60.12M |
| Gross Profit | $72.55M↓ | $74.86M↑ | $63.38M↑ | $59.64M↑ | $51.39M |
| Operating Income | $7.92M↓ | $16.77M↑ | $6.73M↑ | $4.48M↑ | -$3.09M |
| Net Income | $2.23M↓ | $11.08M↑ | $621,000↑ | -$1.93M↑ | -$9.22M |
Peer Comparison
JNJUNHPFE
Fundamentals
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
92.29%
Volume
Today's trading volume
2.50M
Recent News
Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) was among the stocks Jim Cramer commented on, saying that tech stocks cannot be trusted to lead anymore. When a caller mentioned that XERS is their speculative investment, Cramer said: I know it because it’s injectables… But I will tell you this: that’s precisely what I want you to do. […]
Shareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) Earnings
The subdued stock price reaction suggests that Xeris Biopharma Holdings, Inc.'s ( NASDAQ:XERS ) strong earnings didn't...
Results: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise Profit
Investors in Xeris Biopharma Holdings, Inc. ( NASDAQ:XERS ) had a good week, as its shares rose 8.2% to close at...
Xeris Biopharma Q1 Earnings Call Highlights
Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio. On the company’s earnings call, Chief Executive Officer John Shan
Xeris Biopharma Holdings, Inc. Q1 2026 Earnings Call Summary
Moby summary of Xeris Biopharma Holdings, Inc.'s Q1 2026 earnings call